Brookline Capital Markets raised its price target for CTI Biopharma (NASDAQ:CTIC) to $12 from $7.20 after the FDA approved Vonjo in myelofibrosis. The stock closed at $3.10, up $1.20, on volume of 108 million shares on...
Brookline Capital Markets launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $21 price target. The stock closed at $6.10 on Dec. 16. X4 Pharmaceuticals is focused on diseases resulting from...
Brookline Capital Markets launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and a 12-to-18-month price target of $19.00. The stock closed at $8.89 on Nov. 9. Syros is developing gene-control...
Brookline Capital Markets initiated coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with a “buy” rating and $33 price target. The stock closed at $21 on Sept 2. Constellation is using epigenetics to address...